Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
Results
Abstract
All azvudine studies
Meta analysis
 
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, in-hospital 6% Improvement Relative Risk Mortality, day 14 63% Azvudine for COVID-19  Chen et al.  LATE TREATMENT Is late treatment with azvudine beneficial for COVID-19? PSM retrospective 198 patients in China No significant difference in mortality c19early.org Chen et al., Cardiology Plus, April 2023 Favors azvudine Favors control

All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis

Chen et al., Cardiology Plus, doi:10.1097/CP9.0000000000000049
Apr 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Azvudine for COVID-19
41st treatment shown to reduce risk in July 2023
 
*, now known with p = 0.00014 from 18 studies.
Lower risk for mortality, ventilation, ICU admission, progression, and viral clearance.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
PSM retrospective 332 hospitalized moderate to critically ill COVID-19 patients with myocardial injury in China, showing improved 14 day mortality but no difference in overall in-hospital mortality with azvudine treatment.
Important missing comments or errors? Let us know.
risk of death, 6.5% lower, RR 0.94, p = 0.88, treatment 29 of 99 (29.3%), control 31 of 99 (31.3%), NNT 49, in-hospital mortality, propensity score matching.
risk of death, 63.0% lower, HR 0.37, p = 0.007, treatment 99, control 99, propensity score matching, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 30 Apr 2023, retrospective, China, peer-reviewed, 9 authors.
This PaperAzvudineAll
Figure S1. Love plot displaying standardized differences for the baseline characteristics by the use of azvudine in patients with myocardial injuries, before and after propensity score matching. SBP: systolic blood pressure; DBP: diastolic blood pressure; RR: respiratory rate; HR: heart rate
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0